Abstract: The present disclosure provides methods for treating a progressive ovarian cancer using an allogeneic leukemia-derived cell. Also provided are immunogenic compositions comprising an allogeneic leukemia-derived cell, and pharmaceutical compositions and formulations thereof.

Abstract: A method for reducing hemolysis and microparticle formation during storage of pathogen reduced blood. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced hemolysis. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles. Oxygen and pathogen reduced blood compositions comprising CPAD and riboflavin having reduced hemolysis. Oxygen and pathogen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles.

Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg/kg to 18 mg/kg, preferably 8 to 12 mg/kg, more preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases.

Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

Abstract: Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.

Abstract: The present disclosure provides compositions comprising a thermosensitive hydrogel formulation of funapide and a tri-block polymer, and methods of use and manufacture of the compositions for management of acute pain or pain associated with surgical procedure.

Abstract: The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, Fc?RI, FcRN, Transferrin or Macrophage Scavenger receptor. Pharmaceutical compositions based upon these bifunctional small molecules represent an additional aspect of the present invention. These compounds and/or compositions may be used to treat disease states and conditions by removing circulating proteins through degradation in the hepatocytes or macrophages of a patient or subject in need of therapy.

Abstract: The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.

Abstract: The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.

Abstract: Antibodies specific to MUC18 (a.k.a. MCAM or CD146) and antibody-drug conjugates (ADCs) comprising such. Also provided herein are uses the the anti-MUC18 antibodies or ADCs for therapeutic and diagnostic purposes.

Abstract: The present disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a genetic cassette encoding a target sequence. In some embodiments, the target sequence encodes a miRNA and/or a therapeutic protein. In certain embodiments, the therapeutic protein comprises a clotting factor, a growth factor, a hormone, a cytokine, an antibody, a fragment thereof, and a combination thereof. In some embodiments, the first ITR and/or the second ITR is an ITR of a non-adeno-associated virus (AAV). The present disclosure also provides methods of treating a metabolic disorder of the liver in a subject comprising administering to the subject the nucleic acid molecule or a polypeptide encoded thereby.

Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding an immunomodulatory polypeptide (e.g., a pro-inflammatory cytokine such as a human IL-2 or IL-12 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of cancer, such as lung cancer); and articles of manufacture or kits thereof.

Abstract: The present invention relates to a biomarker of epilepsy, a composition for diagnosing epilepsy, an epilepsy-induced animal, and a composition for preventing or treating epilepsy, and specifically, relates to a composition for diagnosing epilepsy comprising a BRAF mutant protein and a nucleic acid molecule, and an agent capable of detecting the protein or nucleic acid molecule, an epilepsy-induced animal transformed with the BRAF mutant nucleic acid molecule, and a composition for prevention or treatment of epilepsy comprising a BRAF mutant protein activity inhibitor.

Abstract: The present disclosure concerns a portable disinfection apparatus, as well as a system and method for tracking disinfection. The apparatus generally comprises an enclosure having an ultraviolet (UV) light source mounted on a rolling mechanism. UV light from the UV light source travels toward a ground surface and disinfects one or more areas or features of the ground surface. The apparatus may also have a scanner or machine reader that reads data encoded on an object each time disinfection occurs. The disinfection events can be logged to create a disinfection event log, thereby tracking the frequency of disinfection events. Additionally, the encoded object may be configured as an image that is placed relative to the floor drain or other to be disinfected such that a user can confirm the apparatus is in the proper location to disinfect the item to be disinfected.

Abstract: A navigation method for a disinfection robot includes: obtaining an initial map within a field of view of the robot; generating a disinfection grid having multiple disinfection squares on the initial map, and determining multiple disinfecting consideration points in the disinfection squares; determining a disinfection order of disinfecting targets corresponding to the disinfection squares according to distances between the robot after the robot completes disinfection of one of the targets corresponding to one of the disinfection squares and to-be-disinfected ones of the disinfection squares; according to distances between the position and the disinfecting consideration points in to-be-disinfected ones of the disinfection squares, combined with priority levels of the disinfecting consideration points in to-be-disinfected ones of the disinfection squares, determining disinfecting planning points in the disinfection squares; and performing disinfection to the targets corresponding to the disinfection squares acc

Abstract: Provided are mobile imaging devices and methods thereof. A mobile imaging device includes a plurality of light source sets, sensors, and a controller. At least one program is non-transiently stored in and executable by the controller. The program causes the controller to perform a method including acquiring a corresponding value for each condition in a first plurality of conditions when the device is at a first position using the sensors to collect a plurality of measurements associated with a region of interest that is not exposed to the plurality of light source sets. The method includes firing with the device held at the first position, if the corresponding value satisfies a corresponding condition specification for a respective condition in the first plurality of conditions, the plurality of light source sets based on a second plurality of conditions. Accordingly, light emits that is substantially limited to a spectral range.

Abstract: A device for sterilizing air from any bacterium, virus, dust or other organic or non-organic body present in the air of a public or private space, using a sterilization chamber having a laser beam filter is provided. A dense network of laser beams which saturate the sterilization chamber is created. The air forced to go through the sterilization chamber causes every small particle, bacterium and virus of any size to impact on the laser beams, pulverizing, destroying and/or neutralizing itself completely by the large beam energy irradiated for a time ranging from 0.5 to 2 seconds.

Abstract: Adhesive wound dressing that comprises an absorbent matrix (A) adhering to the central portion of a polyurethane backing (B) having an adhesive layer for the skin, said matrix (A) comprising: a. a breathable and porous polyethylene film at the end designed to come into contact with the wound; b. an absorbent layer made of non-woven fabric adjacent to film a), said absorbent layer consisting of: i. 60-65% viscose ii. 25-30% polyester iii. 5-15% polypropylene; c. a layer of polyethylene inserted between layer b) and a layer d. of hydrophobic polystyrene, the latter being in contact with the central portion of polyurethane backing (B); wherein matrix (A) is impregnated with a solution of one or more polysaccharides or the salts thereof.

Abstract: An expandable biodegradable hemostatic matrix comprised of oxidized cellulose, and having a density ranging from about 0.8 to about 1.2 gr/cm3 is disclosed herein. The matrix may be expandable to at least 3 times its original volume within 4 sec upon contact with an aqueous solution room temperature. Further disclosed are methods for making the hemostatic matrix as well as method of treating a wound.

Abstract: Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.